Ergoteles’s PDL BioPharma, Inc. PDLI Stock Holding History

Ergoteles’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-11,900	Closed	-$37K	–	1008
2020 Q3	$37K	Buy	+11,900	New	+$38K	﹤0.01%	567

Other funds holding PDLI

SPC

Silver Point Capital Greenwich, Connecticut $1.3B AUM 18.3% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

KBC Group Brussels, Belgium $39.9B AUM 29.7% 1-Year Est. Return

GCIA

Gabelli & Co Investment Advisers Rye, New York $674M AUM 64.52% 1-Year Est. Return

JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return

Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

CCM

Context Capital Management Lajolla, California $4.33B AUM 1.35% 1-Year Est. Return

Winton Group London, United Kingdom $2.85B AUM 30.73% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Ergoteles's PDLI Position: Q4 2020 in Review

Ergoteles sold out of PDL BioPharma, Inc. (PDLI) in Q4 2020, closing a stake of 11,900 shares — an estimated $37K sold.

Ergoteles first reported a position in PDLI in Q3 2020 and held it in 1 quarter. The position peaked at $37K in Q3 2020. 33 funds tracked by Wall St. Rank hold PDLI as of Q4 2020.

Ergoteles reported no remaining PDL BioPharma, Inc. position as of Q4 2020 after selling out during the quarter.
Ergoteles sold 11,900 PDL BioPharma, Inc. shares in Q4 2020, an estimated $37K.
Ergoteles first reported a position in PDL BioPharma, Inc. in Q3 2020 and held it in 1 quarter.
Ergoteles's PDL BioPharma, Inc. position peaked at $37K in Q3 2020.
33 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2020.

Based on Ergoteles's 13F filing for Q4 2020, filed 11 Feb 2021.